Crohn's Disease: The Complete Guide to Medical Management

頁數：488　裝訂：精裝 　開數：28.7*22.3 　印刷：彩色 重量：1.75KG

Product Description
Crohn’s Disease: The Complete Guide to Medical Management serves as the definitive source for medical management of Crohn’s Disease (CD).

Dr. Gary R. Lichtenstein, along with Dr. Ellen J. Scherl, have collaborated with over 60 experts from around the world to provide gastroenterologists and those in training with the necessary information to successfully manage the patient with Crohn’s disease.

Sections Include:
General
The role of the FDA in drug development; pediatric considerations; disease modifiers; and more
Medications
Antibiotic use in treatment of CD; oral budesonide; infliximab; novel biological and non biologic therapies for CD; and more
Specific Clinical Scenarios
Management of steroid unresponsive CD; management of enteric fistulae; use of pre- and probiotics; medical management of short bowel syndrome; maintenance therapy of CD; and more

Features:
--Color images, graphs, and tables
--Extensive index that includes cross-referencing to Ulcerative Colitis: The Complete Guide to Medical Management
--An appendix on Infliximab treatment
--Comprehensive references at the end of each chapter

Organized into an easy-to-reference format, Crohn’s Disease: The Complete Guide to Medical Management threads theory into practice and provides Gastroenterology professionals with the most comprehensive information available on this disease state.

The other side of inflammatory bowel disease is covered in Drs. Gary R. Lichtenstein and Ellen J. Scherl’s Ulcerative Colitis: The Complete Guide to Medical Management. All gastroenterologists will find both books to be essential for future practice in the treatment and care of their patients with either Crohn’s disease or ulcerative colitis, as well as in the overall management of those with inflammatory bowel disease.

Contents
Section I: General

Chapter 1: The Natural History of Inflammatory Bowel Disease

Pietro G. Andres, MD and Lawrence S. Friedman, MD

Chapter 2: Clinical Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials

Chinyu Su, MD and James D. Lewis, MD, MSCE

Chapter 3: The Role of the FDA in Drug Development in Inflammatory Bowel Disease

Alan C. Moss, MD and Adam Cheifetz, MD

Chapter 4: Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease

Ashish Chawla, MD and Kenneth Simpson, BVM&S, PhD

Chapter 5: Pediatric Considerations in Medical Therapy in Patients With Inflammatory Bowel Disease

Louis R. Ghanem, MD, PhD and Robert N. Baldassano, MD

Chapter 6: The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease: What We Do Not Learn From Clinical Trials

Joshua R. Korzenik, MD and Corey A. Siegel, MD

Chapter 7: Disease Modifiers in Inflammatory Bowel Disease

Jaime A. Oviedo, MD and Francis A. Farraye, MD, MSc, FACP, FACG

Chapter 8: Fertility and Pregnancy in Inflammatory Bowel Disease

Jeffry A. Katz, MD and Vinita Elizabeth Jacob, MD

Chapter 9: Medication Adherence in Inflammatory Bowel Disease

Sunanda Kane, MD, MSPH, FACG, FACP, AGAF

Section II: Medications

Chapter 10: Mesalamine for Maintenance Therapy in Ulcerative Colitis: How Much, How Long?

Miles P. Sparrow, MD, MBBS, FRACP; Wee-Chian Lim, MD, MBBS, MMed, MRCP; and Stephen B. Hanauer, MD

Chapter 11: Antibiotic Use in the Treatment of Crohn’s Disease

Manuel Mendizabal, MD; Wojciech Blonski, MD, PhD; David Kotlyar, MD; and Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Chapter 12: Corticosteroids in Crohn’s Disease

Lene Riis, MD and Pia Munkholm, MD, DMSCi

Chapter 13: Oral Budesonide for Inflammatory Bowel Disease

Gordon R. Greenberg, MD, FRCP(C)

Chapter 14: 6-Mercaptopurine and Azathioprine in Crohn’s Disease

Mark T. Osterman, MD and Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Chapter 15: Methotrexate in the Treatment of Crohn’s Disease

Ellen J. Scherl, MD, FACP, AGAF; Arun Swaminath, MD; Ryan Urquhart Warren, MD; and Harrison Lakehomer, BA

Chapter 16: Calcineurin Inhibitors (Cyclosporine A, Tacrolimus, and Sirolimus) and Mycophenolate Mofetil in Crohn’s Disease

Gerassimos J. Mantzaris, MD, PhD, AGAF

Chapter 17: Infliximab in Crohn’s Disease

Lawrence W. Comerford, MD and Stephen J. Bickston, MD, AGAF

Chapter 18: Anti-TNFa Therapy From Symptoms to Molecules: Impact of Individual Variability on Anti-TNFa Optimization Strategies

Ellen J. Scherl, MD, FACP, AGAF

Chapter 19: Novel Biological Therapies for Crohn’s Disease

Iris Dotan, MD and Daniel Rachmilewitz, MD

Chapter 20: Novel Nonbiologic Therapy for Crohn’s Disease

Masayuki Fukata, MD, PhD and Maria T. Abreu, MD

Section III: Specific Clinical Scenarios

Chapter 21: Assessment of Disease Activity in Crohn’s Disease

Alain Bitton, MD, FRCP(C)

Chapter 22: General Principles of Medical Therapy of Crohn’s Disease

Denis Franchimont, MD, PhD and Gary Wild, MD

Chapter 23: Medical Management of Severe Crohn’s Disease

Themistocles Dassopoulos, MD and Theodore M. Bayless, MD

Chapter 24: Medical Management of Enteric Fistulae in Crohn’s Disease

Mamoon Raza, MD and Charles N. Bernstein, MD

Chapter 25: Management of Refractory Crohn’s Disease

Herbert Tilg, MD and Arthur Kaser, MD

Chapter 26: Medical Management of Postoperative Recurrence of Crohn’s Disease

Geert D’Haens MD, PhD and David N. Moskovitz, MD, FRCP(C)

Chapter 27: Management of Steroid-Unresponsive Crohn’s Disease

Sarathchandra I. Reddy, MD, MPH and Robert Burakoff, MD, MPH, FACG, FACP

Chapter 28: Pre- and Probiotics in Crohn’s Disease

Robert M. Penner, BSc, MD, FRCP(C), MSc; Karen L. Madsen, PhD; and Richard N. Fedorak, MD, FRCP(C)

Chapter 29: Management of Crohn’s Disease in the Ileal-Pouch Anal Anastomosis

Gilaad G. Kaplan MD, FRCP(C) and Remo Panaccione MD, FRCP(C)

Chapter 30: Dietary Manipulations: Enteral Therapy for Crohn’s Disease

Alan L. Buchman, MD, MSPH

Chapter 31: Dietary Manipulations: Parenteral Therapy for Crohn’s Disease

Alan L. Buchman, MD, MSPH

Chapter 32: Gastroduodenal/Proximal Crohn’s Disease

Ellen J. Scherl, MD, FACP, AGAF; Brian P. Bosworth, MD; Felice Schnoll-Sussman, MD; Douglas M. Weine, MD; and Peter H. R. Green, MD

Chapter 33: Medical Management of Perianal Fistula

Tarun Misra, MD, FRCP(C) and Richard N. Fedorak, MD, FRCP(C)

Chapter 34: Medical Therapy of Diarrhea Following Bowel Resection

Henry J. Binder, MD

Chapter 35: Short Bowel Syndrome

Jane E. Onken, MD, MHS

Chapter 36: Medical Management of the Patient With an Ostomy

Aaron Brzezinski, MD, FRCP(C)

Chapter 37: Maintenance Therapy of Crohn’s Disease

Wojciech Blonski, MD, PhD; Faten Aberra, MD, MSCE; and Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Appendix: Infliximab Treatment

Financial Disclosures
Index